1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition.
Cephalalgia 2018;38:1-211.
2. Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, et al. Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study.
Cephalalgia 2010;30:207-213.
3. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population.
Cephalalgia 2011;31:1015-1022.
4. Jellestad PL, Carlsen LN, Westergaard ML, Munksgaard SB, Bendtsen L, Lainez M, et al. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project.
Cephalalgia 2019;39:274-285.
5. Zwart JA, Dyb G, Hagen K, Ødegård KJ, Dahl AA, Bovim G, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study.
Eur J Neurol 2003;10:147-152.
6. GBD 2015 Disease and Injury incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet 2016;388:1545-1602.
7. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide.
J Headache Pain 2015;16:58.
8. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet Neurol 2017;16:877-897.
9. Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).
Cephalalgia 2020;40:241-254.
10. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial.
Cephalalgia 2019;39:1075-1085.
11. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Neurol 2017;16:425-434.
12. Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine.
N Engl J Med 2017;377:2123-2132.
13. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine.
N Engl J Med 2017;377:2113-2122.
14. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.
JAMA 2018;319:1999-2008.
15. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study.
Neurology 2018;91:e2211-e2221.
16. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Cephalalgia 2018;38:1442-1454.
17. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.
JAMA Neurol 2018;75:1080-1088.
18. Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, et al. Medication overuse in a subgroup analysis of phase 3 placebocontrolled studies of galcanezumab in the prevention of episodic and chronic migraine.
Cephalalgia 2021;41:340-352.
19. Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medicationoveruse headache: subgroup analysis of PROMISE-2.
Headache 2021;61:125-136.
20. Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
J Headache Pain 2020;21:114.
21. Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial.
Neurology 2019;92:e2309-e2320.
22. Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, et al. European Academy of Neurology guideline on the management of medication-overuse headache.
Eur J Neurol 2020;27:1102-1116.
23. Bendtsen L, Birk S, Kasch H, Aegidius K, Sørensen PS, Thomsen LL, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd edition, 2012.
J Headache Pain 2012;13 Suppl 1:S1-S29.
24. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.
Cephalalgia 1988;8 Suppl 7:1-96.
25. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition.
Cephalalgia 2004;24 Suppl 1:9-160.
26. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II)--revision of criteria for 8.2 medication-overuse headache.
Cephalalgia 2005;25:460-465.
27. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version).
Cephalalgia 2013;33:629-808.
28. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review.
Cephalalgia 2014;34:409-425.
29. Wang SJ, Fuh JL, Lu SR, Liu CY, Hsu LC, Wang PN, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up.
Neurology 2000;54:314-319.
30. Prencipe M, Casini AR, Ferretti C, Santini M, Pezzella F, Scaldaferri N, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication.
J Neurol Neurosurg Psychiatry 2001;70:377-381.
31. Westergaard ML, Glümer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status.
Pain 2014;155:2005-2013.
32. Shand B, Goicochea MT, Valenzuela R, Fadic R, Jensen R, Tassorelli C, et al. Clinical and demographical characteristics of patients with medication overuse headache in argentina and Chile: analysis of the Latin American section of COMOESTAS project.
J Headache Pain 2015;16:83.
33. Park HK, Chu MK, Oh SY, Moon HS, Song TJ, Lee MJ, et al. Interim analysis of the Registry for Load and Management of Medication Overuse Headache (RELEASE): a multicenter, comprehensive medication overuse headache registry.
Cephalalgia 2022;42:455-465.
34. Schwedt TJ, Hentz JG, Sahai-Srivastava S, Spare NM, Martin VT, Treppendahl C, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: crosssectional observations from the medication overuse treatment strategy trial.
Headache 2021;61:351-362.
35. Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial.
JAMA Neurol 2020;77:1069-1078.
36. Viana M, De Icco R, Allena M, Sances G, Højland JR, Katsarava Z, et al. Clinical subtypes of medication overuse headache - findings from a large cohort.
Headache 2019;59:1481-1491.
37. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management.
Nat Rev Neurol 2016;12:575-583.
38. Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project).
Cephalalgia 2014;34:426-433.
39. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs.
Cephalalgia 2006;26:1097-1105.
40. Kristoffersen ES, Straand J, Vetvik KG, Benth JŠ, Russell MB, Lundqvist C. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial.
J Neurol Neurosurg Psychiatry 2015;86:505-512.
41. Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Lasting improvement of medication-overuse headache after brief intervention - a long-term follow-up in primary care.
Eur J Neurol 2017;24:883-891.
42. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness.
Cephalalgia 2006;26:1192-1198.
43. Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medicationoveruse headache: a randomized controlled open-label trial.
Cephalalgia 2018;38:225-236.
44. Rossi P, Jensen R, Nappi G, Allena M. A narrative review on the management of medication overuse headache: the steep road from experience to evidence.
J Headache Pain 2009;10:407-417.
45. Katsarava Z, Obermann M. Medication-overuse headache.
Curr Opin Neurol 2013;26:276-281.
46. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs.
Neurology 2001;57:1694-1698.
47. Relja G, Granato A, Bratina A, Antonello RM, Zorzon M. Outcome of medication overuse headache after abrupt in-patient withdrawal.
Cephalalgia 2006;26:589-595.
48. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache.
Cephalalgia 2000;20:107-113.
49. Paolucci M, Altamura C, Brunelli N, Rizzo AC, Assenza F, Pasqualetti P, et al. Methylprednisolone plus diazepam i.v. as bridge therapy for medication overuse headache.
Neurol Sci 2017;38:2025-2029.
50. Bøe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.
Neurology 2007;69:26-31.
51. Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache.
Cephalalgia 2008;28:152-156.
52. Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study.
Cephalalgia 2013;33:202-207.
53. Cevoli S, Giannini G, Favoni V, Terlizzi R, Sancisi E, Nicodemo M, et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study.
J Headache Pain 2017;18:56.
54. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate.
J Headache Pain 2018;19:50.
55. Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, et al. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
Cephalalgia 2022;42:645-653.
56. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Cephalalgia 2010;30:804-814.
57. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial.
Cephalalgia 2010;30:793-803.
58. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Headache 2010;50:921-936.
59. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
J Neurol Sci 2013;331:48-56.
60. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
J Headache Pain 2011;12:427-433.
61. Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Brain 2019;142:1203-1214.
62. Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse.
Cephalalgia 2009;29:1021-1027.
63. Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial.
Eur Neuropsychopharmacol 2014;24:1289-1297.
64. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review.
Cephalalgia 2016;36:371-386.
65. Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study.
Headache 2017;57:60-70.
66. Tassorelli C, Jensen R, Allena M, De Icco R, Katsarava Z, Miguel Lainez J, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study.
Cephalalgia 2017;37:1115-1125.